Novotech

After spending the week at DIA China 2026, one thing stood out clearly: China and US drug development strategies are becoming increasingly connected. A lot of the conversations this year focused on: 🔹 earlier global planning 🔹 outbound licensing activity 🔹 operational execution 🔹 and how companies manage increasingly cross-border programs Marina Mullins, Vice President, Early Clinical Development and Martin GUAN，管一青, Vice President, Head of Lab at Novotech have pulled together a few observations from the week in our latest blog. Read more here: https://lnkd.in/geSSM4wQ #Globalization #DIA2026 #DrugDevelopment

Today marks one of the most important days in our industry, International Clinical Trials Day. It’s a chance to recognize the people behind every clinical trial, those coordinating across regions, solving problems as they arise, and keeping progress on track. Clinical trials are complex, but they move forward because of the people involved at every step. At Novotech, we are proud to partner with teams around the world who are helping shape the future of healthcare through clinical research. #ClinicalTrials #ClinicalResearch #ICTD2026

APAC is increasingly becoming the strategic launchpad for global oncology development. Read our most recent blog on this topic: https://lnkd.in/gC9QRZ_z In this new piece, Dr. Steven Cha, MD Therapeutic Strategy Lead, Oncology and Tanja Obradovic, PhD, Therapeutic Strategy Lead, Oncology explore how oncology programs have become more biomarker-driven and globally interconnected, and how sponsors are using APAC earlier to generate evidence that can support international regulatory and commercial pathways from the outset. Other points of discussion: 🔹Why APAC is becoming central to early oncology strategy 🔹How dose optimization and biomarker planning affect global scalability 🔹Why operational execution now directly influences evidence quality and portability For sponsors, the challenge is no longer just accelerating recruitment. It’s designing oncology programs capable of generating globally credible evidence from the beginning. #Oncology #ClinicalTrials

How do you accelerate early-phase oncology trials without compromising recruitment quality? Read our latest case study: https://lnkd.in/gzMjwSce A China-based biotech partnered with Novotech to deliver a Phase I/II solid tumor trial in Australia, with ambitious startup and recruitment timelines. The outcome: 🔹 Ethics submission completed in under one week 🔹 Ethics approval in under seven weeks 🔹 First patient enrolled within one week of approval 🔹 51 patients enrolled, exceeding the original target of 30 The case study demonstrates how strategic collaboration, accelerated start-up execution, and targeted site selection can help sponsors advance early-phase oncology programs more efficiently. #Oncology #ClinicalTrials #Biotech #DrugDevelopment

At AACR 2026, alongside the scientific discussions, sponsor conversations placed increasing focus on how programs will be executed in practice. Following these discussions, Steven Cha, MD, Therapeutic Strategy Lead at Novotech, highlighted a shift in how sponsors are approaching study design, with greater emphasis on delivering decision-relevant outcomes on time. As modalities become more complex and patient populations more defined, scientific design and operational delivery are increasingly aligned. Key observations: 🔹 Geography is being incorporated earlier in program design 🔹 Site-level execution is receiving greater focus as protocol complexity increases 🔹 Early- and late-phase programs are prioritizing different definitions of speed These factors are shaping how oncology trials are planned and delivered across regions. Hear more from Steven: https://lnkd.in/gArCtd8p #AACR2026 #Oncology #ClinicalDevelopment #Biotech #ClinicalTrials

Where should Japanese biotechs run their first clinical trial? It’s a question many sponsors are asking as Japan’s regulatory reforms make it easier to use international clinical data in domestic submissions. Leaders from GEXVal and FerroptoCure joined Novotech in a discussion moderated by Citeline to explore how these changes are reshaping early development strategies. For many companies, early-phase studies outside Japan are becoming part of the pathway. Australia is often considered for its efficient trial start-up timelines and globally recognized data. But one point stood out: the choice of development partner matters just as much as the location. For biotech companies with limited time and capital, working with a CRO that understands both the Japanese regulatory landscape and the realities of running trials in Australia can shape the entire development path. Read the full discussion here: https://lnkd.in/gPgPu6na #Biotech #ClinicalTrials #DrugDevelopment #Japan

We’re really pleased to be working with Noxopharm Limited as they progress SOF-SKN™ toward a pre-IND meeting with the US FDA. Early regulatory milestones are such an important moment in a program’s journey, we’re glad to be part of it.

Oncology trials are becoming more complex and getting them right early matters. Meet Novotech at #ASCO2026. Request a meeting: https://lnkd.in/dwCACwq8 We’ve conducted more than 800 oncology trials across Phases I–IV, supporting sponsors across APAC, North America, and Europe. Novotech will be on site with a global team of senior leaders, regional experts, and oncology strategy specialists across APAC, North America, and Europe. Our team including Dr. Anand Tharmaratnam, CEO, Barry Murphy, Chief Commercial Officer, and Dr. Judith Ng-Cashin, Chief Medical Officer, alongside regional and functional leaders across therapeutic strategy, clinical operations, and business development will be on site to discuss: 🔹 How to improve patient recruitment across regions 🔹 How to work more effectively with investigators and sites 🔹 What we’re seeing across key oncology markets If you're planning an upcoming oncology study, we can help you plan with greater confidence. #ASCO2026 #Oncology #ClinicalTrials #Biotech

As Australia’s largest CRO, Novotech is proud to join the Australian delegation in Boston on May 14. Steve Roan, Associate Business Development Director at Novotech, will discuss the benefits of Australia for both healthy volunteer and patient studies, along with strategies to accelerate timelines and support successful study outcomes. https://lnkd.in/gu97gnAd

Where is oncology development really accelerating and how should sponsors respond? At Bionnova, Raymond Jia, VP Clinical Services Asia at Novotech, shared how the global oncology landscape is changing, and what that means for development strategy. Themes that stood out: 🔹Oncology now accounts for 41% of all trials globally 🔹China is now a core hub of oncology innovation, not just execution 🔹Early-phase risk is driving more strategic MRCT design across regions 🔹APAC is becoming central to faster, more efficient global development pathways 🔹True speed comes from how effectively regions are selected and sequenced from the outset. For sponsors planning early oncology development, this comes down to where to run trials, when to expand, and how to manage risk. If we missed you at Bionova, feel free to contact us: https://lnkd.in/g7cHJSBB #Oncology #ClinicalTrials #Biotech #DrugDevelopment